173 related articles for article (PubMed ID: 35977671)
41. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
42. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
43. Multicentric development and evaluation of [
Lucia F; Louis T; Cousin F; Bourbonne V; Visvikis D; Mievis C; Jansen N; Duysinx B; Le Pennec R; Nebbache M; Rehn M; Hamya M; Geier M; Salaun PY; Schick U; Hatt M; Coucke P; Hustinx R; Lovinfosse P
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1097-1108. PubMed ID: 37987783
[TBL] [Abstract][Full Text] [Related]
44. Machine learning based evaluation of clinical and pretreatment
Nakajo M; Jinguji M; Tani A; Yano E; Hoo CK; Hirahara D; Togami S; Kobayashi H; Yoshiura T
Abdom Radiol (NY); 2022 Feb; 47(2):838-847. PubMed ID: 34821963
[TBL] [Abstract][Full Text] [Related]
45. A different overview of staging PET/CT images in patients with esophageal cancer: the role of textural analysis with machine learning methods.
Karahan Şen NP; Aksu A; Çapa Kaya G
Ann Nucl Med; 2021 Sep; 35(9):1030-1037. PubMed ID: 34106428
[TBL] [Abstract][Full Text] [Related]
46. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
47. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
48. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
[TBL] [Abstract][Full Text] [Related]
50. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
51. Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma.
Zhao HY; Su YX; Zhang LH; Fu P
Neoplasma; 2022 Jan; 69(1):233-241. PubMed ID: 34779641
[TBL] [Abstract][Full Text] [Related]
52. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
[TBL] [Abstract][Full Text] [Related]
53. Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR.
Vuong D; Tanadini-Lang S; Huellner MW; Veit-Haibach P; Unkelbach J; Andratschke N; Kraft J; Guckenberger M; Bogowicz M
Med Phys; 2019 Apr; 46(4):1677-1685. PubMed ID: 30714158
[TBL] [Abstract][Full Text] [Related]
54. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Seol HY; Kim YS; Kim SJ
Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
56. Pre-treatment
Ahn HK; Lee H; Kim SG; Hyun SH
Clin Radiol; 2019 Jun; 74(6):467-473. PubMed ID: 30898382
[TBL] [Abstract][Full Text] [Related]
57. Combination of
Li S; Li Y; Zhao M; Wang P; Xin J
Korean J Radiol; 2022 Sep; 23(9):921-930. PubMed ID: 36047542
[TBL] [Abstract][Full Text] [Related]
58. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
59. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of maximum standardized uptake value on
Qiu X; Liang H; Zhong W; Zhao J; Chen M; Zhu Z; Xu Y; Wang M
Thorac Cancer; 2021 Mar; 12(6):845-853. PubMed ID: 33512768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
